<DOC>
	<DOC>NCT01604798</DOC>
	<brief_summary>No ideal serum biomarker currently exists for the early diagnosis of colorectal cancer (CRC). Therefore, it is urgent that accurate and reliable serum biomarkers be identified.</brief_summary>
	<brief_title>Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer</brief_title>
	<detailed_description>Magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) was used to screen serum samples from CRC patients and healthy controls.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients with colorectal cancer Inclusion criteria histologically confirmed colorectal cancer aged 18 years or older have provided written informed consent Exclusion criteria refusal to participate Healthy controls Inclusion criteria no cancer history aged 18 years or older have provided written informed consent Exclusion criteria refusal to participate have firstdegree relative with a known history of colorectal cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>proteomics</keyword>
	<keyword>serum peptides</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>MALDI-TOF MS</keyword>
</DOC>